Brokerages Anticipate RTI Surgical Inc (RTIX) to Post $0.04 Earnings Per Share

RTI Surgical Inc (NASDAQ:RTIX) has been given an average broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.

Zacks has also assigned RTI Surgical an industry rank of 97 out of 256 based on the ratings given to related companies.

A number of research analysts have issued reports on the stock. ValuEngine lowered shares of RTI Surgical from a “buy” rating to a “hold” rating in a report on Tuesday, December 25th. BidaskClub upgraded shares of RTI Surgical from a “sell” rating to a “hold” rating in a report on Tuesday, September 25th.

NASDAQ:RTIX traded up $0.05 on Wednesday, reaching $3.86. The stock had a trading volume of 4,240 shares, compared to its average volume of 95,055. The firm has a market cap of $236.71 million, a price-to-earnings ratio of 77.20 and a beta of 1.33. The company has a current ratio of 3.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.27. RTI Surgical has a 12-month low of $3.51 and a 12-month high of $5.10.

RTI Surgical (NASDAQ:RTIX) last released its earnings results on Thursday, November 1st. The medical equipment provider reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.02. The company had revenue of $69.06 million for the quarter, compared to analyst estimates of $70.09 million. RTI Surgical had a negative net margin of 3.91% and a positive return on equity of 4.04%. On average, equities research analysts forecast that RTI Surgical will post 0.11 earnings per share for the current fiscal year.

In related news, CFO Jonathon M. Singer purchased 50,000 shares of the firm’s stock in a transaction dated Wednesday, December 12th. The stock was acquired at an average price of $4.28 per share, with a total value of $214,000.00. Following the completion of the transaction, the chief financial officer now owns 264,844 shares of the company’s stock, valued at $1,133,532.32. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Camille Farhat purchased 17,185 shares of the firm’s stock in a transaction dated Thursday, December 6th. The shares were bought at an average cost of $4.04 per share, with a total value of $69,427.40. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 78,701 shares of company stock worth $327,764. Insiders own 4.40% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC boosted its holdings in RTI Surgical by 70.9% in the third quarter. Citadel Advisors LLC now owns 35,571 shares of the medical equipment provider’s stock worth $160,000 after purchasing an additional 14,760 shares during the period. Marshall Wace LLP acquired a new position in RTI Surgical in the third quarter worth $297,000. ClariVest Asset Management LLC boosted its holdings in RTI Surgical by 20.4% in the second quarter. ClariVest Asset Management LLC now owns 67,697 shares of the medical equipment provider’s stock worth $311,000 after purchasing an additional 11,486 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in RTI Surgical by 16.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 125,900 shares of the medical equipment provider’s stock worth $580,000 after purchasing an additional 17,600 shares during the period. Finally, Strs Ohio boosted its holdings in RTI Surgical by 7.7% in the second quarter. Strs Ohio now owns 155,800 shares of the medical equipment provider’s stock worth $716,000 after purchasing an additional 11,100 shares during the period. 69.79% of the stock is owned by institutional investors and hedge funds.

About RTI Surgical

RTI Surgical, Inc, together with its subsidiaries, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes.

See Also: Backdoor Roth IRA Conversion and Strategy

Get a free copy of the Zacks research report on RTI Surgical (RTIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit